BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21196202)

  • 21. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis.
    Stolz C; Hess G; Hähnel PS; Grabellus F; Hoffarth S; Schmid KW; Schuler M
    Blood; 2008 Oct; 112(8):3312-21. PubMed ID: 18689543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies.
    Winiarska M; Glodkowska-Mrowka E; Bil J; Golab J
    Front Biosci (Landmark Ed); 2011 Jan; 16(1):277-306. PubMed ID: 21196171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate.
    Sieber S; Gdynia G; Roth W; Bonavida B; Efferth T
    Int J Oncol; 2009 Jul; 35(1):149-58. PubMed ID: 19513562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Rituximab: mechanism of action and resistance].
    Dalle S; Dumontet C
    Bull Cancer; 2007 Feb; 94(2):198-202. PubMed ID: 17337389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms.
    Harjunpää A; Junnikkala S; Meri S
    Scand J Immunol; 2000 Jun; 51(6):634-41. PubMed ID: 10849376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
    Lv M; Lin Z; Qiao C; Gen S; Lang X; Li Y; Feng J; Shen B
    Cancer Lett; 2010 Aug; 294(1):66-73. PubMed ID: 20202740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy.
    Vega GG; Franco-Cea LA; Huerta-Yepez S; Mayani H; Morrison SL; Bonavida B; Vega MI
    Int J Oncol; 2015 Nov; 47(5):1735-48. PubMed ID: 26398317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversal of Resistance to Anti-CD20 Antibody Therapies: Targeting Intracellular Resistant Factors.
    Navasardyan I; Bonavida B
    Crit Rev Oncog; 2020; 25(3):275-290. PubMed ID: 33463946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.
    Manches O; Lui G; Chaperot L; Gressin R; Molens JP; Jacob MC; Sotto JJ; Leroux D; Bensa JC; Plumas J
    Blood; 2003 Feb; 101(3):949-54. PubMed ID: 12393572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
    Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
    J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis.
    Jazirehi AR; Gan XH; De Vos S; Emmanouilides C; Bonavida B
    Mol Cancer Ther; 2003 Nov; 2(11):1183-93. PubMed ID: 14617792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy.
    Friedberg JW
    Hematology Am Soc Hematol Educ Program; 2005; ():329-34. PubMed ID: 16304399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis.
    Baritaki S; Militello L; Malaponte G; Spandidos DA; Salcedo M; Bonavida B
    Int J Oncol; 2011 Jun; 38(6):1683-94. PubMed ID: 21455568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.
    Cruz RI; Hernandez-Ilizaliturri FJ; Olejniczak S; Deeb G; Knight J; Wallace P; Thurberg BL; Kennedy W; Czuczman MS
    Leuk Lymphoma; 2007 Dec; 48(12):2424-36. PubMed ID: 18067019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMab.
    Zhao L; Xie F; Tong X; Li H; Chen Y; Qian W; Duan S; Zheng J; Zhao Z; Li B; Zhang D; Zhao J; Dai J; Wang H; Hou S; Guo Y
    MAbs; 2014; 6(3):740-8. PubMed ID: 24670986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.
    van Meerten T; van Rijn RS; Hol S; Hagenbeek A; Ebeling SB
    Clin Cancer Res; 2006 Jul; 12(13):4027-35. PubMed ID: 16818702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
    Liu C; DeNardo G; Tobin E; DeNardo S
    Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.
    Golay J; Zaffaroni L; Vaccari T; Lazzari M; Borleri GM; Bernasconi S; Tedesco F; Rambaldi A; Introna M
    Blood; 2000 Jun; 95(12):3900-8. PubMed ID: 10845926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
    Braza MS; Klein B; Fiol G; Rossi JF
    Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias.
    Gupta P; Goldenberg DM; Rossi EA; Chang CH
    Blood; 2010 Oct; 116(17):3258-67. PubMed ID: 20628151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.